You just read:

Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and Relative Durability with Complete Responses at Highest Dose Levels

News provided by

Trovagene, Inc.

Apr 01, 2019, 13:00 ET